Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Health Lobbying Means Cash Infusion For Candidates, TV StationsKaiser
"Health care groups working feverishly to shape -- or kill -- an industry-wide reform bill are lavishing campaign cash on the politicians at the center of the debate," The Salt Lake (Utah) Tribune reports. Sens. Orrin Hatch and Max Baucus, both major health reform players on the Senate Finance Committee, are among those benefiting form the uptick in contributions. One lobbyist for the watchdog group Public Citizen said, "A person can reach no other conclusion than this is quid pro quo activity" (Canham, 7/27).

New Nice Guideline For Type 2 Diabetes Recognises Benefits From Newer Agents For Blood Glucose Control
Merck Sharp & Dohme Limited (MSD) welcomes the publication of the guideline for type 2 diabetes newer agents1 from the National Institute for Health and Clinical Excellence (NICE) in the UK, which recommends considering a range of newer therapy options, including "Januvia" (sitagliptin). The guideline recommends that the DPP-4 inhibitor class, which includes sitagliptin, should be considered as a second line therapy instead of a sulphonylurea (SU) when blood glucose control remains or becomes inadequate (HbA1c ð‰¥ 6.5% or other higher level agreed with the individual) with metformin in patients at significant risk of hypoglycaemia or its consequences, or if a patient does not tolerate an SU or an SU is contraindicated.1
News of the day
Protein Structures Revealed At Record Pace
Scientists at the U.S. Department of Energy"s (DOE) Lawrence Berkeley National Laboratory have developed a fast and efficient way to determine the structure of proteins, shortening a process that often takes years into a matter of days.
Medical Devices

Cost-Effectiveness Of HPV Vaccination In The Netherlands

Even under favorable assumptions, including lifelong protection against 70% of all cervical cancers and no side effects, vaccination against the human papillomavirus (HPV) is not cost-effective in the Netherlands, according to a study published online July 1 in the Journal of the National Cancer Institute. Researchers conducted the study because the cost effectiveness of HPV vaccination may be limited by the low number of cervical cancer cases and deaths in the region associated with the current Dutch cervical cancer screening program. In the study, Inge M.C.M. de Kok of the Department of Public Health at Erasmus MC, University Medical Center in Rotterdam, the Netherlands, and colleagues estimated the costs and effects of adding HPV vaccination to the current program (screening only) using a microsimulation screening analysis model. They found that adding HPV vaccination was not cost-effective, even under favorable assumptions. "To become cost-effective, the vaccine price would have to be decreased considerably, depending on the effectiveness of the vaccine," the authors write. Steve Graff Journal of the National Cancer Institute


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009